Media Pack
News

Current Edition

JCS Volume 15 Issue 4
 
news

Nanobiotix presents first promising data from Phase I/II Liver Cancers trial of NBTXR3 at the American Society Of Clinical Oncology Gastrointestinal Annual Meeting

NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces a f...
24 January 2018 news enrollment | liver cancer
Continue Reading →
news

Tianhe Life Sciences leads $9.5m Series A in Clover Biopharma

Tianhe Life Sciences leads $9.5m Series A in Clover Biopharma Clover is utilising its proprietary Trimer-Tag technology platform to develop biologics targeting trimer...
20 December 2017 news biologics | clinical development
Continue Reading →
news

Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3’s significant potential role in Immuno-Oncology at SITC Annual Meeting

Nanobiotix, a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, recently presented positive clinical and preclinical data...
15 November 2017 news cancer | clinical
Continue Reading →
news

Cmed to Demonstrate how encapsia® Transforms Clinical Trial Data Management, Capture and Reporting at Leading Oncology Meetings

Cmed, an oncology focused, innovative technology-led CRO, today announced that it will showcase its encapsia® clinical data suite at two leading oncology meetings, Cl...
15 November 2017 news clinical trial | CRO
Continue Reading →
 
 

jcs-white.png

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

Facebook Linkedin
Journal For Clinical Studies © 2024, All Rights Reserved – Powered by Teksyte